26 results on '"Vlodavsky, Israel"'
Search Results
2. Regulatory T cells use heparanase to access IL-2 bound to extracellular matrix in inflamed tissue.
- Author
-
Martinez, Hunter A., Koliesnik, Ievgen, Kaber, Gernot, Reid, Jacqueline K., Nagy, Nadine, Barlow, Graham, Falk, Ben A., Medina, Carlos O., Hargil, Aviv, Zihsler, Svenja, Vlodavsky, Israel, Li, Jin-Ping, Pérez-Cruz, Magdiel, Tang, Sai-Wen, Meyer, Everett H., Wrenshall, Lucile E., Lord, James D., Garcia, K. Christopher, Palmer, Theo D., and Steinman, Lawrence
- Subjects
REGULATORY T cells ,EXTRACELLULAR matrix ,T cells ,HEPARANASE ,HEPARAN sulfate proteoglycans ,HEPARAN sulfate ,T cell receptors - Abstract
Although FOXP3
+ regulatory T cells (Treg) depend on IL-2 produced by other cells for their survival and function, the levels of IL-2 in inflamed tissue are low, making it unclear how Treg access this critical resource. Here, we show that Treg use heparanase (HPSE) to access IL-2 sequestered by heparan sulfate (HS) within the extracellular matrix (ECM) of inflamed central nervous system tissue. HPSE expression distinguishes human and murine Treg from conventional T cells and is regulated by the availability of IL-2. HPSE-/- Treg have impaired stability and function in vivo, including in the experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis. Conversely, endowing monoclonal antibody-directed chimeric antigen receptor (mAbCAR) Treg with HPSE enhances their ability to access HS-sequestered IL-2 and their ability to suppress neuroinflammation in vivo. Together, these data identify a role for HPSE and the ECM in immune tolerance, providing new avenues for improving Treg-based therapy of autoimmunity. Regulatory T cell (Treg ) maintenance and function require IL-2, yet this cytokine is only present in low levels in vivo. In this study, the authors demonstrate that that Treg use heparanase to access IL-2 bound to heparan sulfate proteoglycans in the extracellular matrix of inflamed brain tissue in mice. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
3. miR-184 represses β-catenin and behaves as a skin tumor suppressor.
- Author
-
Turovsky, Lubov, Kheshaiboun, Ghazal, Yassen, Gharam, Nagosa, Sara, Boyango, Ilanit, Amitai-Lange, Aya, Bhattacharya, Swarnabh, Ilan, Neta, Vlodavsky, Israel, Aberdam, Daniel, Shalom-Feuerstein, Ruby, and Avitan-Hersh, Emily
- Published
- 2024
- Full Text
- View/download PDF
4. Heparanase 2 (Hpa2)- a new player essential for pancreatic acinar cell differentiation.
- Author
-
Kayal, Yasmin, Barash, Uri, Naroditsky, Inna, Ilan, Neta, and Vlodavsky, Israel
- Published
- 2023
- Full Text
- View/download PDF
5. Non-enzymatic heparanase enhances gastric tumor proliferation via TFEB-dependent autophagy.
- Author
-
Yang, Min, Tang, Bo, Wang, Sumin, Tang, Li, Wen, Dalin, Vlodavsky, Israel, and Yang, Shi-Ming
- Published
- 2022
- Full Text
- View/download PDF
6. Dichotomic role of heparanase in a murine model of metabolic syndrome.
- Author
-
Hermano, Esther, Carlotti, Françoise, Abecassis, Alexia, Meirovitz, Amichay, Rubinstein, Ariel M., Li, Jin-Ping, Vlodavsky, Israel, Rabelink, Ton J., and Elkin, Michael
- Subjects
HEPARANASE ,METABOLIC syndrome ,INSULIN sensitivity ,METABOLIC models ,TYPE 2 diabetes - Abstract
Heparanase is the predominant enzyme that cleaves heparan sulfate, the main polysaccharide in the extracellular matrix. While the role of heparanase in sustaining the pathology of autoimmune diabetes is well documented, its association with metabolic syndrome/type 2 diabetes attracted less attention. Our research was undertaken to elucidate the significance of heparanase in impaired glucose metabolism in metabolic syndrome and early type 2 diabetes. Here, we report that heparanase exerts opposite effects in insulin-producing (i.e., islets) vs. insulin-target (i.e., skeletal muscle) compartments, sustaining or hampering proper regulation of glucose homeostasis depending on the site of action. We observed that the enzyme promotes macrophage infiltration into islets in a murine model of metabolic syndrome, and fosters β-cell-damaging properties of macrophages activated in vitro by components of diabetogenic/obese milieu (i.e., fatty acids). On the other hand, in skeletal muscle (prototypic insulin-target tissue), heparanase is essential to ensure insulin sensitivity. Thus, despite a deleterious effect of heparanase on macrophage infiltration in islets, the enzyme appears to have beneficial role in glucose homeostasis in metabolic syndrome. The dichotomic action of the enzyme in the maintenance of glycemic control should be taken into account when considering heparanase-targeting strategies for the treatment of diabetes. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Correction: Non-enzymatic heparanase enhances gastric tumor proliferation via TFEB-dependent autophagy.
- Author
-
Yang, Min, Tang, Bo, Wang, Sumin, Tang, Li, Wen, Dalin, Vlodavsky, Israel, and Yang, Shi-Ming
- Published
- 2023
- Full Text
- View/download PDF
8. Processing of heparanase is mediated by syndecan-1 cytoplasmic domain and involves syntenin and α-actinin.
- Author
-
Shteingauz, Anna, Ilan, Neta, and Vlodavsky, Israel
- Subjects
HEPARANASE ,SYNDECANS ,CYTOPLASM ,ACTININ ,METASTASIS - Abstract
Heparanase activity plays a decisive role in cell dissemination associated with cancer metastasis. Cellular uptake of heparanase is considered a pre-requisite for the delivery of latent 65-kDa heparanase to lysosomes and its subsequent proteolytic processing and activation into 8- and 50-kDa protein subunits by cathepsin L. Heparan sulfate proteoglycans, and particularly syndecan, are instrumental for heparanase uptake and activation, through a process that has been shown to occur independent of rafts. Nevertheless, the molecular mechanism underlying syndecan-mediated internalization outside of rafts is unclear. Here, we examined the role of syndecan-1 cytoplasmic domain in heparanase processing, utilizing deletion constructs lacking the entire cytoplasmic domain (Delta), the conserved (C1 or C2), or variable (V) regions. Heparanase processing was markedly increased following syndecan-1 over-expression; in contrast, heparanase was retained at the cell membrane and its processing was impaired in cells over-expressing syndecan-1 deleted for the entire cytoplasmic tail. We have next revealed that conserved domain 2 (C2) and variable (V) regions of syndecan-1 cytoplasmic tail mediate heparanase processing. Furthermore, we found that syntenin, known to interact with syndecan C2 domain, and α actinin are essential for heparanase processing. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Molecular and Cellular Aspects of Heparanase.
- Author
-
Marmé, Dieter, Fusenig, Norbert, Ilan, Neta, Fux, Liat, Elkin, Michael, and Vlodavsky, Israel
- Abstract
Heparanase is an endoglycosidase involved in cleavage of heparan sulfate and hence in degradation and remodeling of the basement membrane and extracellular matrix (ECM). Heparanase activity facilitates cell invasion associated with cancer metastasis, angiogenesis, autoimmunity and inflammation. The enzyme is preferentially expressed in human tumors and its over-expression in tumor cells confers an invasive phenotype. Heparanase also releases angiogenic factors from the ECM and thereby induces an angiogenic response in vivo. Heparanase upregulation correlates with increased tumor vascularity and poor postoperative survival of cancer patients. Moreover, heparanase levels in the urine and plasma of cancer patients often correlate with the severity of the disease and response to anti-cancer treatments. These observations, the anti-cancerous effect of heparanase gene silencing and of heparanase-inhibiting molecules, as well as the unexpected identification of a single functional heparanase, suggest that the enzyme is a valid target for anti-cancer drug development and a promising tumor marker. Heparanase also exhibits non-enzymatic activities, stimulating, among other effects, cell adhesion, Akt signaling and PI3K-dependent endothelial cell migration and invasion. It also promotes VEGF expression via the Src pathway and hence may activate endothelial cells and elicit angiogenic and survival responses. Studies with heparanase over-expressing transgenic mice revealed that the enzyme functions in normal processes (i.e., wound healing) involving cell mobilization, HS turnover, tissue vascularization and remodeling. Inhibitors directed against domains critical for heparanase secretion and signaling, combined with inhibitors of heparanase enzymatic activity (i.e., nonanticoagulant glycol-split heparin) are being developed to halt tumor growth, angiogenesis and metastasis. In this review, we summarize the current status of heparanase' research, emphasizing molecular and cellular aspects of the enzyme, including its mode of processing and activation, control of heparanase gene expression, cytoplasmic vs. nuclear localization, enzymatic and non-enzymatic functions, causal involvement in cancer metastasis and angiogenesis, and strategies for the development of heparanase inhibitors. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
10. Heparanase.
- Author
-
Vlodavsky, Israel
- Subjects
- *
DEFINITIONS , *MAMMALS , *ENZYMES , *GLUCURONIDASE , *SULFATES - Abstract
A definition of the term "heparanase," is presented, which refers to a mammalian enzyme, that is endo-β-glucuronidase, degrading heparan sulfate, a ubiquitous strongly anionic linear polysaccharide associated with the cell surface and extracellular matrix of a wide range of cells of vertebrate and invertebrate tissues.
- Published
- 2001
11. Heparanase is preferentially expressed in human psoriatic lesions and induces development of psoriasiform skin inflammation in mice.
- Author
-
Lerner, Immanuel, Zcharia, Eyal, Neuman, Tzahi, Hermano, Esther, Rubinstein, Ariel, Vlodavsky, Israel, and Elkin, Michael
- Subjects
HEPARANASE ,PSORIATIC arthritis ,SKIN inflammation ,LABORATORY mice ,ENZYME inhibitors ,NF-kappa B ,KERATINOCYTES - Abstract
Heparanase is the sole mammalian endoglycosidase that selectively degrades heparan sulfate, the key polysaccharide associated with the cell surface and extracellular matrix of a wide range of tissues. Extensively studied for its capacity to promote cancer progression, heparanase enzyme was recently implicated as an important determinant in several inflammatory disorders as well. Applying immunohistochemical staining, we detected preferential expression of heparanase by epidermal keratinocytes in human psoriatic lesions. To investigate the role of the enzyme in the pathogenesis of psoriasis, we utilized heparanase transgenic mice in a model of 12- O-tetradecanoyl phorbol 12-myristate 13-acetate-induced cutaneous inflammation. We report that over-expression of the enzyme promotes development of mouse skin lesions that strongly recapitulate the human disease in terms of histomorphological appearance and molecular/cellular characteristics. Importantly, heparanase of epidermal origin appears to facilitate abnormal activation of skin-infiltrating macrophages, thus generating psoriasis-like inflammation conditions, characterized by induction of STAT3, enhanced NF-κB signaling, elevated expression of TNF-α and increased vascularization. Taken together, our results reveal, for the first time, involvement of heparanase in the pathogenesis of psoriasis and highlight a role for the enzyme in facilitating abnormal interactions between immune and epithelial cell subsets of the affected skin. Heparanase inhibitors (currently under clinical testing in malignant diseases) could hence turn highly beneficial in psoriatic patients as well. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
12. Heparanase overexpression impairs inflammatory response and macrophage-mediated clearance of amyloid-β in murine brain.
- Author
-
Zhang, Xiao, Wang, Bo, O'Callaghan, Paul, Hjertström, Elina, Jia, Juan, Gong, Feng, Zcharia, Eyal, Nilsson, Lars, Lannfelt, Lars, Vlodavsky, Israel, Lindahl, Ulf, and Li, Jin-Ping
- Subjects
HEPARANASE ,AMYLOID beta-protein precursor genetics ,LABORATORY mice ,TREATMENT of neurodegeneration ,MACROPHAGE activation ,HEPARAN sulfate proteoglycans ,MICROINJECTION (Cytology) - Abstract
Neuroinflammation is typically observed in neurodegenerative diseases such as Alzheimer's disease, as well as after traumatic injury and pathogen infection. Resident immune cells, microglia and astrocytes, are activated and joined by blood-borne monocytes that traverse the blood-brain barrier and convert into activated macrophages. The activated cells express various cytokines, chemokines and proteolytic enzymes. To study the role of heparan sulfate proteoglycans in neuroinflammation, we employed a transgenic mouse overexpressing heparanase, an endoglucuronidase that specifically degrades heparan sulfate side chains. Neuroinflammation was induced by systemic challenge with lipopolysaccharide, or by localized cerebral microinjection of aggregated amyloid-β peptide, implicated in Alzheimer's disease. Lipopolysaccharide-treated control mice showed massive activation of resident microglia as well as recruitment of monocyte-derived macrophages into the brain parenchyma. Microinjection of aggregated amyloid-β elicited a similar inflammatory response, albeit restricted to the injection site, which led to dispersion and clearance of the amyloid. In the heparanase-overexpressing mice, all aspects of immune cell recruitment and activation were significantly attenuated in both inflammation models, as was amyloid dispersion. Accordingly, an in vitro blood-brain barrier model constructed from heparanase-overexpressing cerebral vascular cells showed impaired transmigration of monocytes compared to a corresponding assembly of control cells. Our data indicate that intact heparan sulfate chains are required at multiple sites to mediate neuroinflammatory responses, and further point to heparanase as a modulator of this process, with potential implications for Alzheimer's disease. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
13. Significance of Heparanase in Cancer and Inflammation.
- Author
-
Vlodavsky, Israel, Beckhove, Phillip, Lerner, Immanuel, Pisano, Claudio, Meirovitz, Amichai, Ilan, Neta, and Elkin, Michael
- Abstract
Heparan sulfate proteoglycans (HSPGs) are primary components at the interface between virtually every eukaryotic cell and its extracellular matrix. HSPGs not only provide a storage depot for heparin-binding molecules in the cell microenvironment, but also decisively regulate their accessibility, function and mode of action. As such, they are intimately involved in modulating cell invasion and signaling loops that are critical for tumor growth, inflammation and kidney function. In a series of studies performed since the cloning of the human heparanase gene, we and others have demonstrated that heparanase, the sole heparan sulfate degrading endoglycosidase, is causally involved in cancer progression, inflammation and diabetic nephropathy and hence is a valid target for drug development. Heparanase is causally involved in inflammation and accelerates colon tumorigenesis associated with inflammatory bowel disease. Notably, heparanase stimulates macrophage activation, while macrophages induce production and activation of latent heparanase contributed by the colon epithelium, together generating a vicious cycle that powers colitis and the associated tumorigenesis. Heparanase also plays a decisive role in the pathogenesis of diabetic nephropathy, degrading heparan sulfate in the glomerular basement membrane and ultimately leading to proteinuria and kidney dysfunction. Notably, clinically relevant doses of ionizing radiation (IR) upregulate heparanase expression and thereby augment the metastatic potential of pancreatic carcinoma. Thus, combining radiotherapy with heparanase inhibition is an effective strategy to prevent tumor resistance and dissemination in IR-treated pancreatic cancer patients. Also, accumulating evidence indicate that peptides derived from human heparanase elicit a potent anti-tumor immune response, suggesting that heparanase represents a promising target antigen for immunotherapeutic approaches against a broad variety of tumours. Oligosaccharide-based compounds that inhibit heparanase enzymatic activity were developed, aiming primarily at halting tumor growth, metastasis and angiogenesis. Some of these compounds are being evaluated in clinical trials, targeting both the tumor and tumor microenvironment. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
14. The heparanase system and tumor metastasis: is heparanase the seed and soil?
- Author
-
Arvatz, Gil, Shafat, Itay, Levy-Adam, Flonia, Ilan, Neta, and Vlodavsky, Israel
- Abstract
Tumor metastasis, the leading cause of cancer patients' death, is still insufficiently understood. While concepts and mechanisms of tumor metastasis are evolving, it is widely accepted that cancer metastasis is accompanied by orchestrated proteolytic activity executed by array of proteases. While matrix metalloproteinases (MMPs) attracted much attention, other proteases constitute the tumor milieu, of which a large family consists of cysteine proteases named cathepsins. Like MMPs, some cathepsins are often upregulated in cancer and, once secreted or localized to the cell surface, can degrade components of the extracellular matrix. In addition, cathepsin L is held responsible for processing and activation of heparanase, an endo-β-glucuronidase capable of cleaving heparan sulfate side chains of heparan sulfate proteoglycans, activity that is strongly implicated in cell dissemination associated with tumor metastasis, angiogenesis, and inflammation. In this review, we discuss recent progress in heparanase research focusing on heparanase-related molecules namely, cathepsin L and heparanase 2 (Hpa2), a heparanase homolog. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
15. Transgenic or tumor-induced expression of heparanase upregulates sulfation of heparan sulfate.
- Author
-
Escobar Galvis, Martha L, Juan Jia, Xiao Zhang, Jastrebova, Nadja, Spillmann, Dorothe, Gottfridsson, Eva, van Kuppevelt, Toin H., Zcharia, Eyal, Vlodavsky, Israel, Lindahl, Ulf, and Jin-Ping Li
- Subjects
SULFATES ,PROTEINS ,TISSUES ,HEPARIN ,FIBROBLAST growth factors ,PROTEOGLYCANS ,HOMEOSTASIS ,TUMORS - Abstract
Heparan sulfate proteoglycans (HSPGs) interact with numerous proteins of importance in animal development and homeostasis. Heparanase, which is expressed in normal tissues and upregulated in angiogenesis, cancer and inflammation, selectively cleaves β-glucuronidic linkages in HS chains. In a previous study, we transgenically overexpressed heparanase in mice to assess the overall effects of heparanase on HS metabolism. Metabolic labeling confirmed extensive fragmentation of HS in vivo. In the current study we found that in liver showing excessive heparanase overexpression, HSPG turnover is accelerated along with upregulation of HS N- and O-sulfation, thus yielding heparin-like chains without the domain structure typical of HS. Heparanase overexpression in other mouse organs and in human tumors correlated with increased 6-O-sulfation of HS, whereas the domain structure was conserved. The heavily sulfated HS fragments strongly promoted formation of ternary complexes with fibroblast growth factor 1 (FGF1) or FGF2 and FGF receptor 1. Heparanase thus contributes to regulation of HS biosynthesis in a way that may promote growth factor action in tumor angiogenesis and metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
16. Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma.
- Author
-
Davidson, Ben, Vintman, Lina, Zcharia, Eyal, Bedrossian, Carlos, Berner, Aasmund, Nielsen, Søren, Ilan, Neta, Vlodavsky, Israel, and Reich, Reuven
- Abstract
Heparanase is an endoglycosidase that degrades heparan sulfate (HS) in the extracellular matrix (ECM) and cell surfaces, and fulfills a significant role in cancer metastasis and angiogenesis. We evaluated the expression of heparanase and its possible association with the expression of angiogenic molecules in malignant mesothelioma (MM), and analyzed whether expression of these proteins is site-related (pleural vs peritoneal MM, solid lesions vs effusions). Sections from 80 MM (56 biopsies, 24 effusions) were analyzed for heparanase protein expression using immunohistochemistry (IHC). Sixty MM were of pleural origin, and 20 were peritoneal. Effusion specimens consisted of 6 peritoneal and 18 pleural effusions, while biopsies consisted of 14 peritoneal and 42 pleural lesions. Fifty-four specimens were additionally evaluated for expression of basic fibroblast growth factor (bFGF), interleukin-8 (IL-8) and vascular endothelial growth factor (VEGF) proteins using IHC. Microvessel density (MVD) was studied in 28 biopsies using an anti-CD31 antibody. mRNA expression of heparanase (HPSE-1), VEGF and the VEGF receptor KDR was analyzed in 23 effusions using RT-PCR. Heparanase protein expression was seen in 69/80 (86%) tumors. Of these, 35 showed combined membrane and cytoplasmic expression, 30 cytoplasmic expression, and four exclusively membrane expression. Both total ( P= 0.001) and cytoplasmic ( P = 0.002) expression was significantly higher in solid tumors compared to effusions. Protein expression of VEGF, IL-8 and bFGF was seen in 21/54 (39%), 22/54 (41%) and 44/54 (81%) specimens, respectively. Protein expression of bFGF was significantly higher in solid tumors ( P 0.001) and correlated with heparanase expression ( P = 0.005). HPSE-1 and VEGF mRNA expression was detected in all 23 effusions using RT-PCR, while KDR mRNA was found in 12/23 MM. KDR mRNA expression correlated with that of both HPSE-1 ( P = 0.005) and VEGF ( P = 0.001). Our results document frequent expression of heparanase in MM, in agreement with the biological aggressiveness of this tumor. The co-expression of heparanase with bFGF is in agreement with the role of the former in releasing bFGF from the ECM. The concomitant reduction in protein expression of both molecules in effusions as compared to solid tumors, supports the hypothesis of a reduced need for pro-angiogenic stimuli in effusions, and may aid in defining tumor progression in this setting. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
17. PADMA-28, a traditional Tibetan herbal preparation, blocks cellular responses to bFGF and IGF-I.
- Author
-
Navab, Roya, Aingorn, Helena, Fallavollita, Lucia, Sallon, Sara, Mechoulam, Raphael, Ginsburg, Isaac, Vlodavsky, Israel, and Brodt, Pnina
- Subjects
ATHEROSCLEROSIS ,CORONARY restenosis ,FIBROBLAST growth factors ,SOMATOMEDIN ,GROWTH factors ,PATHOLOGICAL physiology - Abstract
The growth factors basic fibroblast growth factor (bFGF) and insulin-like growth factor 1 (IGF-I) have been implicated in the pathophysiology of atherosclerosis and restenosis. The Tibetan herbal preparation PADMA-28 (a mixture of 22 plants which is used as an anti-atherosclerosis agent) was tested for its ability to inhibit the mitogenic activity of bFGF and IGF-I, growth factors involved in restenosis, atherosclerosis and tumour progression. DNA synthesis and proliferation of vascular smooth muscle cells, in response to serum bFGF, thrombin, or combinations thereof, were abrogated in the presence of microgram amounts of both the aqueous and organic, partially purified, extracts of PADMA-28. These fractions also inhibited IGF-I-mediated proliferation, migration and invasion of tumour cells responsive to IGF-I. The inhibition by PADMA 28 was reversible upon removal of the PADMA extracts, indicating that the effects were not related to cell toxicity. These and other properties (i.e., anti-oxidant activity) of PADMA-28 may be responsible for its beneficial effect as an anti-atherosclerotic agent, suggesting that this herbal preparation may have potential applications in the prevention of intimal hyperplasia and arterial stenosis secondary to coronary angioplasty and bypass surgery, as well as in the prevention and treatment of other vascular diseases and tumour growth and metastasis. [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
18. Role of promoter methylation in regulation of the mammalian heparanase gene.
- Author
-
Shteper, Pesach J, Zcharia, Eyal, Ashhab, Yaqoub, Peretz, Tamar, Vlodavsky, Israel, and Ben-Yehuda, Dina
- Subjects
METHYLATION ,PROTEOGLYCANS ,NEOVASCULARIZATION ,GLIOMAS ,HISTONES - Abstract
Mammalian heparanase (endo-ß-glucuronidase) degrades heparan sulfate proteoglycans and is an important modulator of the extracellular matrix and associated factors. The enzyme is preferentially expressed in neoplastic tissues and contributes to tumour metastasis and angiogenesis. To investigate the epigenetic regulation of the heparanase locus, methylation-specific and bisulfite PCR were performed on a panel of 22 human cancer cell lines. Cytosine methylation of the heparanase promoter was associated with inactivation of the affected allele. Despite lack of sequence homology, extensively methylated CpG islands were found both in human choriocarcinoma (JAR) and rat glioma (C-6) cells which lack heparanase activity. Treatment of these cells with demethylating agents (5-azacytidine, 5-aza-2'-deoxycytidine) resulted in stable dose- and time-dependant promoter hypomethylation accompanied by reappearance of heparanase mRNA, protein and enzymatic activity. An inhibitor of histone deacetylase, Trichostatin A, failed to induce either of these effects. Upregulation of heparanase expression and activity by demethylating drugs was associated with a marked increase in lung colonization by pretreated C-6 rat glioma cells. The increased metastatic potential in vivo was inhibited in mice treated with laminaran sulfate, a potent inhibitor of heparanase activity. We propose a model wherein expression of mammalian heparanase gene is modulated by the interplay between trans-activating genetic and cis-inhibitory epigenetic elements in its promoter.Oncogene (2003) 22, 7737-7749. doi:10.1038/sj.onc.1207056 [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
19. Molecular Properties and Involvement of Heparanase in Cancer Progression and Mammary Gland Morphogenesis.
- Author
-
Zcharia, Eyal, Metzger, Shula, Chajek-Shaul, Tova, Friedmann, Yael, Pappo, Orit, Aviv, Ayelet, Elkin, Michael, Pecker, Iris, Peretz, Tamar, and Vlodavsky, Israel
- Abstract
Tumor spread involves degradation of various components of the extracellular matrix and blood vessel wall. Among these is heparan sulfate proteoglycan, which plays a key role in the self-assembly, insolubility and barrier properties of basement membranes and extracellular matrices. Expression of an endoglycosidase (heparanase) which degrades heparan sulfate correlates with the metastatic potential of tumor cells, and treatment with heparanase inhibitors markedly reduces the incidence of metastasis in experimental animals. Heparin-binding angiogenic proteins are stored as a complex with heparan sulfate in the microenvironment of tumors. These proteins are released and can induce new capillary growth when heparan sulfate is degraded by heparanase. Here, we describe the molecular properties, expression and involvement in tumor progression of a human heparanase. The enzyme is synthesized as a latent ∼65 kDa protein that is processed at the N-terminus into a highly active ∼50 kDa form. The heparanase mRNA and protein are preferentially expressed in metastatic human cell lines and in tumor biopsy specimens, including breast carcinoma. Overexpression of the heparanase cDNA in low-metastatic tumor cells conferred a high metastatic potential in experimental animals, resulting in an increased rate of mortality. The heparanase enzyme also released ECM-resident bFGF in vitro, and its overexpression elicited an angiogenic response in vivo. Heparanase may thus facilitate both tumor cell invasion and neovascularization, two critical steps in tumor progression. Mammary glands of transgenic mice overexpressing the heparanase enzyme exhibit precocious branching of ducts and alveolar development, suggesting that the enzyme promotes normal morphogenesis and possibly pre-malignant changes in the mammary gland. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
20. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis.
- Author
-
Vlodavsky, Israel, Friedmann, Yael, Elkin, Michael, Aingorn, Helena, Atzmon, Ruth, Ishai-Michaeli, Rivka, Bitan, Menachem, Pappo, Orit, Peretz, Tuvia, Michal, Israel, Spector, Larissa, and Pecker, Iris
- Subjects
- *
ENZYMES , *EXTRACELLULAR matrix , *MOLECULAR cloning - Abstract
Heparan sulfate proteoglycans interact with many extracellular matrix constituents, growth factors and enzymes. Degradation of heparan sulfate by endoglycosidic heparanase cleavage affects a variety of biological processes. We have purified a 50-kDa heparanase from human hepatoma and placenta, and now report cloning of the cDNA and gene encoding this enzyme. Expression of the cloned cDNA in insect and mammalian cells yielded 65-kDa and 50-kDa recombinant heparanase proteins. The 50-kDa enzyme represents an N-terminally processed enzyme, at least 100-fold more active than the 65-kDa form. The heparanase mRNA and protein are preferentially expressed in metastatic cell lines and specimens of human breast, colon and liver carcinomas. Low metastatic murine T-lymphoma and melanoma cells transfected with the heparanase cDNA acquired a highly metastatic phenotype in vivo, reflected by a massive liver and lung colonization. This represents the first cloned mammalian heparanase, to our knowledge, and provides direct evidence for its role in tumor metastasis. Cloning of the heparanase gene enables the development of specific molecular probes for early detection and treatment of cancer metastasis and autoimmune disorders. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
21. Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase.
- Author
-
Naparstek, Yaakov, Cohen, Irun R., Fuks, Zvi, and Vlodavsky, Israel
- Published
- 1984
- Full Text
- View/download PDF
22. Thrombin receptor overexpression in malignant and physiological invasion processes.
- Author
-
Even-Ram, Sharona, Uziely, Beatrice, Cohen, Patrizia, Grisaru-Granovsky, Sorina, Maoz, Miriam, Ginzburg, Yoav, Reich, Reuven, Vlodavsky, Israel, and Bar-Shavit, Rachel
- Published
- 1998
- Full Text
- View/download PDF
23. Respective roles of laminin and fibronectin in adhesion of human carcinoma and sarcoma cells.
- Author
-
Vlodavsky, Israel and Gospodarowicz, Denis
- Published
- 1981
- Full Text
- View/download PDF
24. Systemic LPS-induced Aβ-solubilization and clearance in AβPP-transgenic mice is diminished by heparanase overexpression.
- Author
-
Jendresen, Charlotte, Digre, Andreas, Cui, Hao, Zhang, Xiao, Vlodavsky, Israel, Li, Jin-Ping, and Nilsson, Lars N. G.
- Abstract
Amyloid-β (Aβ) is the main constituent of amyloid deposits in Alzheimer's disease (AD). The neuropathology is associated with neuroinflammation. Here, we investigated effects of systemic lipopolysaccharide (LPS)-treatment on neuroinflammation and Aβ deposition in AβPP-mice and double-transgenic mice with brain expression of AβPP and heparanase, an enzyme that degrades HS and generates an attenuated LPS-response. At 13 months of age, the mice received a single intraperitoneal injection of 50 µg LPS or vehicle, and were sacrificed 1.5 months thereafter. Aβ in the brain was analyzed histologically and biochemically after sequential detergent extraction. Neuroinflammation was assessed by CD45 immunostaining and mesoscale cytokine/chemokine ELISA. In single-transgenic mice, LPS-treatment reduced total Aβ deposition and increased Tween-soluble Aβ. This was associated with a reduced CXCL1, IL-1β, TNF-α-level and microgliosis, which correlated with amyloid deposition and total Aβ. In contrast, LPS did not change Aβ accumulation or inflammation marker in the double-transgenic mice. Our findings suggest that a single pro-inflammatory LPS-stimulus, if given sufficient time to act, triggers Aβ-clearance in AβPP-transgenic mouse brain. The effects depend on HS and heparanase. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Overexpression of heparanase enhances T lymphocyte activities and intensifies the inflammatory response in a model of murine rheumatoid arthritis.
- Author
-
Digre, Andreas, Singh, Kailash, Åbrink, Magnus, Reijmers, Rogier M., Sandler, Stellan, Vlodavsky, Israel, and Li, Jin-Ping
- Abstract
Heparanase is an endo-glucuronidase that degrades heparan sulfate chains. The enzyme is expressed at a low level in normal organs; however, elevated expression of heparanase has been detected in several inflammatory conditions, e.g. in the synovial joints of rheumatoid arthritis (RA) patients. Herein, we have applied the model of collagen-induced arthritis (CIA) to transgenic mice overexpressing human heparanase (Hpa-tg) along with wildtype (WT) mice. About 50% of the induced animals developed clinical symptoms, i.e. swelling of joints, and there were no differences between the Hpa-tg and WT mice in the incidence of disease. However, Hpa-tg mice displayed an earlier response and developed more severe symptoms. Examination of cells from thymus, spleen and lymph nodes revealed increased innate and adaptive immune responses of the Hpa-tg mice, reflected by increased proportions of macrophages, antigen presenting cells and plasmacytoid dendritic cells as well as Helios-positive CD4
+ and CD8+ T cells. Furthermore, splenic lymphocytes from Hpa-tg mice showed higher proliferation activity. Our results suggest that elevated expression of heparanase augmented both the innate and adaptive immune system and propagated inflammatory reactions in the murine RA model. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
26. Difference in the cellular cholesterol to phospholipid ratio in normal lymphocytes and lymphocytic leukaemic cells.
- Author
-
VLODAVSKY, ISRAEL and SACHS, LEO
- Published
- 1974
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.